Journal: Journal of thrombosis and haemostasis : JTH

Article Title: Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents

doi: 10.1111/jth.14148

Figure Lengend Snippet: Schematic depiction and representative examples of rotational thromboelastometry (ROTEM) traces recorded during recalcification, tissue factor (TF) and TF/tissue-type plasminogen activator (t-PA) ROTEM assays with whole blood from treated FVIII−/− rats. (A) Schematic depiction of a ROTEM curve that demonstrates where clot initiation, propagation, stabilization, lysis and dissolution of a formed thrombus can be detected. (B) Representative examples of recorded ROTEM traces from the recalcified whole blood assay, which assesses global clot formation. (C) Representative examples of recorded ROTEM traces for the TF assay, which assesses global clot formation following activation of coagulation with TF. (D) Representative examples of ROTEM traces for the TF/t-PA assay, which assesses the formation and stability of clots following addition of t-PA to all blood samples. Each trace in (B), (C) and (D) shows the rat whole blood sample that best represented its treatment group on the basis of mean clotting time and maximum clot firmness results. rFVIIa, recombinant activated factor VII; TXA, tranexamic acid; WT, wild-type.

Article Snippet: Whole blood coagulation profiles were obtained by use of a ROTEM delta hemostasis analyzer (TEM International, Munich, Germany) and prewarmed plastic test cups.

Techniques: Lysis, Whole Blood Assay, Transcription Factor Assay, Activation Assay, Coagulation, Recombinant

Journal: Anesthesiology

Article Title: Coagulopathy Underlying Rotational Thromboelastometry Derangements in Trauma Patients: A Prospective Observational Multicenter Study

doi: 10.1097/aln.0000000000004268

Figure Lengend Snippet: Fig. 1. Coagulation factor levels stratified by ROTEM derangement. Median and interquartile ranges of (A) fibrinogen, (B) factor II, (C) factor V, (D) factor VII, (E) factor VIII, (F) factor IX, (G) factor X, and (H) factor XIII per coagulation group based on admission ROTEM profile. An asterisk above the bar represents a statistically significant difference compared to the group of patients with a normal ROTEM profile, * P < 0.05, ** P < 0.01, *** P < 0.001. N, patients with a normal ROTEM profile; ↑CTex, clotting time EXTEM > 80 s; ↓CA5ex, EXTEM clot amplitude at 5 min < 40 mm; ↓CA5fib, FIBTEM clot amplitude at 5 min < 10 mm; ↓CA5ex+fib, EXTEM clot amplitude at 5 min < 40 mm and FIBTEM clot amplitude at 5 min < 10 mm; ↑CT & ↓CA5ex+fib, EXTEM clotting time > 80 s, EXTEM clot amplitude at 5 min < 40 mm and FIBTEM clot amplitude at 5 min < 10 mm; ↓CA5ex+fib & ↓Li30, EXTEM clot amplitude at 5 min < 40 mm, FIBTEM clot amplitude at 5 min < 10 mm and lysis index at 30 min < 85%; All deranged, EXTEM clotting time > 80 s, EXTEM clot amplitude at 5 min < 40 mm, FIBTEM clot amplitude at 5 min < 10 mm and lysis index at 30 min < 85%.

Article Snippet: Mauch J, Spielmann N, Hartnack S, Madjdpour C, Kutter AP, Bettschart-Wolfensberger R, Weiss M, Haas T: Intrarater and interrater variability of point of care coagulation testing using the ROTEM delta.

Techniques: Coagulation, FIBTEM Assay, Lysis

Journal: Anesthesiology

Article Title: Coagulopathy Underlying Rotational Thromboelastometry Derangements in Trauma Patients: A Prospective Observational Multicenter Study

doi: 10.1097/aln.0000000000004268

Figure Lengend Snippet: Fig. 2. Fibrinolysis marker levels stratified by ROTEM derangement. Median and interquartile ranges of (A) D-dimer, (B) α2-antiplasmin, (C) plasmin antiplasmin complexes, and (D) tissue plasminogen activator per coagulation group based on admission ROTEM profile. An asterisk above the bar represents a statistically significant difference compared to the group of patients with a normal ROTEM profile, * P < 0.05, ** P < 0.01, *** P < 0.001. N, patients with a normal ROTEM profile; ↑CTex, clotting time EXTEM > 80 s; ↓CA5ex, EXTEM clot amplitude at 5 min < 40 mm; ↓CA5fib, FIBTEM clot amplitude at 5 min < 10 mm; ↓CA5ex+fib, EXTEM clot amplitude at 5 min < 40 mm and FIBTEM clot amplitude at 5 min < 10 mm; ↑CT & ↓CA5ex+fib, EXTEM clotting time > 80 s, EXTEM clot amplitude at 5 min < 40 mm and FIBTEM clot amplitude at 5 min < 10 mm; ↓CA5ex+fib & ↓Li30, EXTEM clot amplitude at 5 min < 40 mm, FIBTEM clot amplitude at 5 min < 10 mm and lysis index at 30 min < 85%; All deranged, EXTEM clotting time > 80 s, EXTEM clot amplitude at 5 min < 40 mm, FIBTEM clot amplitude at 5 min < 10 mm and lysis index at 30 min < 85%.

Article Snippet: Mauch J, Spielmann N, Hartnack S, Madjdpour C, Kutter AP, Bettschart-Wolfensberger R, Weiss M, Haas T: Intrarater and interrater variability of point of care coagulation testing using the ROTEM delta.

Techniques: Marker, Coagulation, FIBTEM Assay, Lysis